These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 30355697)

  • 1.
    An Y; Parsons LM; Jankowska E; Melnyk D; Joshi M; Cipollo JF
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30355697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of N-linked glycosylation on hemagglutinins derived from chicken embryos and MDCK cells: a case of the production of a trivalent seasonal influenza vaccine.
    Li J; Liu S; Gao Y; Tian S; Yang Y; Ma N
    Appl Microbiol Biotechnol; 2021 May; 105(9):3559-3572. PubMed ID: 33937925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.
    Zost SJ; Parkhouse K; Gumina ME; Kim K; Diaz Perez S; Wilson PC; Treanor JJ; Sant AJ; Cobey S; Hensley SE
    Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12578-12583. PubMed ID: 29109276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.
    Schmeisser F; Jing X; Joshi M; Vasudevan A; Soto J; Li X; Choudhary A; Baichoo N; Resnick J; Ye Z; McCormick W; Weir JP
    Influenza Other Respir Viruses; 2016 Mar; 10(2):134-40. PubMed ID: 26616263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies.
    Verma S; Soto J; Vasudevan A; Schmeisser F; Alvarado-Facundo E; Wang W; Weiss CD; Weir JP
    PLoS One; 2017; 12(4):e0175733. PubMed ID: 28423025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the potency of a cell-based seasonal quadrivalent influenza vaccine using a purified primary liquid standard.
    Takahashi H; Fujimoto T; Horikoshi F; Uotani T; Okutani M; Shimasaki N; Hamamoto I; Odagiri T; Nobusawa E
    Biologicals; 2020 Nov; 68():32-39. PubMed ID: 33023810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China.
    Li C; Shao M; Cui X; Song Y; Li J; Yuan L; Fang H; Liang Z; Cyr TD; Li F; Li X; Wang J
    Biologicals; 2010 Mar; 38(2):284-9. PubMed ID: 20074976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production and antigenic properties of influenza virus from suspension MDCK-siat7e cells in a bench-scale bioreactor.
    Chu C; Lugovtsev V; Lewis A; Betenbaugh M; Shiloach J
    Vaccine; 2010 Oct; 28(44):7193-201. PubMed ID: 20800699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.
    Medina J; Boukhebza H; De Saint Jean A; Sodoyer R; Legastelois I; Moste C
    Vaccine; 2015 Aug; 33(35):4221-7. PubMed ID: 26206270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.
    Khurana S; King LR; Manischewitz J; Coyle EM; Golding H
    Vaccine; 2014 Apr; 32(19):2188-97. PubMed ID: 24613520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Y161F Hemagglutinin Substitution Increases Thermostability and Improves Yields of 2009 H1N1 Influenza A Virus in Cells.
    Wen F; Li L; Zhao N; Chiang MJ; Xie H; Cooley J; Webby R; Wang PG; Wan XF
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity.
    Hütter J; Rödig JV; Höper D; Seeberger PH; Reichl U; Rapp E; Lepenies B
    J Immunol; 2013 Jan; 190(1):220-30. PubMed ID: 23225881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines.
    Bodle J; Vandenberg K; Laurie K; Barr IG; Zhang Y; Rockman S
    Front Immunol; 2023; 14():1147028. PubMed ID: 37033922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.
    Cruz E; Cain J; Crossett B; Kayser V
    Hum Vaccin Immunother; 2018 Mar; 14(3):508-517. PubMed ID: 29048990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of an Egg-Adapted Influenza A(H3N2) Virus without Amino Acid Substitutions at the Antigenic Sites of Its Hemagglutinin.
    Kuwahara T; Takashita E; Fujisaki S; Shirakura M; Nakamura K; Kishida N; Takahashi H; Suzuki N; Kawaoka Y; Watanabe S; Odagiri T
    Jpn J Infect Dis; 2018 May; 71(3):234-238. PubMed ID: 29709975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.
    Khurana S; Larkin C; Verma S; Joshi MB; Fontana J; Steven AC; King LR; Manischewitz J; McCormick W; Gupta RK; Golding H
    Vaccine; 2011 Aug; 29(34):5657-65. PubMed ID: 21704111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of glycosylation to influenza A virus hemagglutinin modulates antibody-mediated recognition of H1N1 2009 pandemic viruses.
    Job ER; Deng YM; Barfod KK; Tate MD; Caldwell N; Reddiex S; Maurer-Stroh S; Brooks AG; Reading PC
    J Immunol; 2013 Mar; 190(5):2169-77. PubMed ID: 23365085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial.
    Treanor JJ; Schiff GM; Hayden FG; Brady RC; Hay CM; Meyer AL; Holden-Wiltse J; Liang H; Gilbert A; Cox M
    JAMA; 2007 Apr; 297(14):1577-82. PubMed ID: 17426277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza.
    Vodeiko GM; Weir JP
    Influenza Other Respir Viruses; 2012 May; 6(3):176-87. PubMed ID: 21902817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.